In Celgene's footsteps

For companies with high-risk drugs, it may be easier to license Celgene Corp.'s use patents for its S.T.E.P.S. risk management and drug dispensing program than to try to create their own programs to get around CELG's IP. CELG granted four non-exclusive licenses to the patents surrounding the company's thalidomide drug-dispensing program last month, and with a little help from FDA, is

Read the full 615 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE